Literature DB >> 21715564

VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations.

Markus P Rechsteiner1, Adriana von Teichman, Anna Nowicka, Tullio Sulser, Peter Schraml, Holger Moch.   

Abstract

Mutations of the von Hippel-Lindau (VHL) gene are frequent in clear cell renal cell carcinomas (ccRCC). Nonsense and frameshift mutations abrogate the function of the VHL protein (pVHL), whereas missense mutations can have different effects. To identify those missense mutations with functional consequences, we sequenced VHL in 256 sporadic ccRCC and identified 187 different VHL mutations of which 65 were missense mutations. Location and destabilizing effects of VHL missense mutations were determined in silico. The majority of the thermodynamically destabilizing missense mutations were located in exon 1 in the core of pVHL, whereas protein surface mutations in exon 3 affected the interaction domains of elongin B and C. Their impact on pVHL's functionality was further investigated in vitro by stably reintroducing VHL missense mutations into a VHL null cell line and by monitoring the green fluorescent protein (GFP) signals after the transfection of a hypoxia inducible factor (HIF)α-GFP expression vector. pVHL's functionality ranged from no effect to complete HIF stabilization. Interestingly, Asn78Ser, Asp121Tyr, and Val130Phe selectively influenced HIF1α and HIF2α degradation. In summary, we obtained three different groups of missense mutations: one with severe destabilization of pVHL; a second without destabilizing effects on pVHL but relevance for the interaction with HIFα, elongin B, and elongin C; and a third with pVHL functions comparable with wild type. We therefore conclude that the specific impact of missense mutations may help to distinguish between driver and passenger mutations and may explain responses of ccRCC patients to HIF-targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21715564     DOI: 10.1158/0008-5472.CAN-11-0757

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  Renal tumors: diagnostic and prognostic biomarkers.

Authors:  Puay Hoon Tan; Liang Cheng; Nathalie Rioux-Leclercq; Maria J Merino; George Netto; Victor E Reuter; Steven S Shen; David J Grignon; Rodolfo Montironi; Lars Egevad; John R Srigley; Brett Delahunt; Holger Moch
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

2.  Mutational status of VHL gene and its clinical importance in renal clear cell carcinoma.

Authors:  Mariana Rezende Alves; Felipe Cavalcanti Carneiro; André Mourão Lavorato-Rocha; Walter Henriques da Costa; Isabela Werneck da Cunha; Stênio de Cássio Zequi; Gustavo Cardoso Guimaraes; Fernando Augusto Soares; Dirce Maria Carraro; Rafael Malagoli Rocha
Journal:  Virchows Arch       Date:  2014-07-16       Impact factor: 4.064

Review 3.  Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background.

Authors:  Lauren Fishbein; Katherine L Nathanson
Journal:  Cancer Genet       Date:  2012 Jan-Feb

4.  Clear cell papillary renal cell carcinoma and renal angiomyoadenomatous tumor: two variants of a morphologic, immunohistochemical, and genetic distinct entity of renal cell carcinoma.

Authors:  Karl-Friedrich Deml; Hans-Ulrich Schildhaus; Eva Compérat; Adriana von Teichman; Martina Storz; Peter Schraml; Joseph V Bonventre; Falko Fend; Barbara Fleige; Andreas Nerlich; Helmut E Gabbert; Nikolaus GaBler; Rainer Grobholz; Seife Hailemariam; Raoul Hinze; Ruth Knüchel; Benoit Lhermitte; Gabriella Nesi; Thomas Rüdiger; Guido Sauter; Holger Moch
Journal:  Am J Surg Pathol       Date:  2015-07       Impact factor: 6.394

5.  Whole genome and transcriptome amplification: practicable tools for sustainable tissue biobanking?

Authors:  Adriana von Teichman; Martina Storz; Susanne Dettwiler; Holger Moch; Peter Schraml
Journal:  Virchows Arch       Date:  2012-09-25       Impact factor: 4.064

6.  Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma.

Authors:  Gunther Boysen; Damaris Bausch-Fluck; Claudio R Thoma; Anna M Nowicka; Daniel P Stiehl; Igor Cima; Van-Duc Luu; Adriana von Teichman; Thomas Hermanns; Tullio Sulser; Barbara Ingold-Heppner; Niklaus Fankhauser; Roland H Wenger; Wilhelm Krek; Peter Schraml; Bernd Wollscheid; Holger Moch
Journal:  Neoplasia       Date:  2012-06       Impact factor: 5.715

7.  Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein.

Authors:  Zhiyong Ding; Peter German; Shanshan Bai; A Srinivas Reddy; Xian-De Liu; Mianen Sun; Lijun Zhou; Xiaohua Chen; Xiaobei Zhao; Chengbiao Wu; Shuxing Zhang; Gordon B Mills; Eric Jonasch
Journal:  Cancer Res       Date:  2014-04-22       Impact factor: 12.701

Review 8.  Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity.

Authors:  Patricia L M Dahia
Journal:  Nat Rev Cancer       Date:  2014-01-20       Impact factor: 60.716

9.  Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing.

Authors:  Dorothee Pflueger; Andrea Sboner; Martina Storz; Jasmine Roth; Eva Compérat; Elisabeth Bruder; Mark A Rubin; Peter Schraml; Holger Moch
Journal:  Neoplasia       Date:  2013-11       Impact factor: 5.715

10.  Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function.

Authors:  P German; S Bai; X-D Liu; M Sun; L Zhou; S Kalra; X Zhang; R Minelli; K L Scott; G B Mills; E Jonasch; Z Ding
Journal:  Oncogene       Date:  2016-03-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.